½ÃÀ庸°í¼­
»óǰÄÚµå
1363170

ÀÇ·á±â±â »óȯ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ÁöºÒÀÚº°, ÇコÄɾî ȯ°æº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)

Medical Devices Reimbursement Market Size, Share & Trends Analysis Report By Payer (Public, Private), By Healthcare Setting (Hospitals, Outpatient Facilities), By Region, And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 275 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÇ·á±â±â »óȯ ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è ÀÇ·á±â±â »óȯ ½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2030³â±îÁö CAGR 8.8%·Î È®´ëµÇ¾î 2030³â¿¡´Â 1Á¶ 282¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÇ·á±â±â »óȯÀº ÀÇ·á±â±â »ç¿ë Áß ¹ß»ýÇÑ ºñ¿ë¿¡ ´ëÇØ Á¦3ÀÚ ¹Î°£ ¶Ç´Â °ø°ø º¸Çè»ç°¡ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿¡°Ô ÁöºÒÇÏ´Â ºñ¿ëÀ¸·Î Á¤Àǵ˴ϴÙ. »ê¾÷ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº »óȯ¿¡ ´ëÇÑ ÀÇÁ¸µµ Áõ°¡, ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ¿¹¹æ ÀÇ·áÀÇ È®´ëÀÔ´Ï´Ù. Á¶±â Áø´Ü ¹× ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ ÁýÁßÀº Áø´Ü ±â±â »ê¾÷ÀÇ È°µ¿À» Ȱ¼ºÈ­ÇÏ°í °á°úÀûÀ¸·Î ´õ ¸¹Àº »óȯ Á¡À¯À²À» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, À¯¹æ¾Ï °ËÁø °­È­¿Í °°Àº Á¶±â Áø´Ü¿¡ ´ëÇÑ º¸»óÀ» ÅëÇØ Á¶±â Áø´Ü¿¡ ´ëÇÑ Àμ¾Æ¼ºê¸¦ Á¦°øÇÏ´Â ±Ùº»ÀûÀÎ ÆÐ·¯´ÙÀÓ ÀüȯÀÌ ½ÅÈï °æÁ¦±Ç Àüü¿¡¼­ ÁÖ¸ñ¹Þ°í ÀÖÀ¸¸ç, COVID-19 ÆÒµ¥¹Í ±â°£ µ¿¾È ·Îº¿ º¸Á¶ ¼ö¼ú°ú °°Àº ¼ö¼úÀº ¿¬±âµÇ¾ú½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹Í ȸº¹±â¿¡´Â ÀϺ»°ú Áß±¹°ú °°Àº ±¹°¡µéÀÌ ¼ö¼úÀÇ Á¤È®µµ¸¦ ³ôÀ̱â À§ÇØ ·Îº¿ Áö¿ø Á¦°øÀÚ¿¡°Ô »óȯÀ» Á¦°øÇÏ´Â µ¥ Àû±ØÀûÀ¸·Î Âü¿©Çϰí Àֱ⠶§¹®¿¡ ƯÈ÷ ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ÀÌ·¯ÇÑ ¼ö¼úÀÌ °³¼±µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ÀÌ´Ï¼ÅÆ¼ºê´Â ÆÒµ¥¹Í ÀÌÈÄ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ÀÇ·á±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ÀÇ·á±â±â »óȯ ¼­ºñ½º´Â ÇコÄÉ¾î »ê¾÷¿¡ ´Ù¾çÇÑ ºñÁö´Ï½º ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, º¸Çè °¡ÀÔÀÚÀÇ Áõ°¡¿Í ÀÇ·á ½Ã½ºÅÛ ÅëÇÕÀº ¾÷°è ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì Áö¿ªÀº 2022³â 50.2% ÀÌ»óÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ±× ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇコÄɾî Àåºñ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÇコÄÉ¾î ¼¾ÅÍÀÇ Áõ°¡°¡ ÀÌ Áö¿ªÀÇ »ê¾÷À» °ßÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ´Ù¾çÇÑ ÀÇ·á±â±â¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ¶ÇÇÑ ÀÌ Áö¿ª ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 1¿ù »çÀ̾𽺠´ÙÀÌ·ºÆ®(Science Direct)Áö¿¡ °ÔÀçµÈ ¿¬±¸¿¡ µû¸£¸é, 2011³âºÎÅÍ 2021³â±îÁö ¿µ»óÁø´Ü °Ë»ç¿¡ ´ëÇÑ ÀÇ·áºñ ÁöÃâÀÌ ²ÙÁØÈ÷ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ ±â°üÀÇ ÀÌ·¯ÇÑ Ãß¼¼°¡ Áö¼ÓµÉ °æ¿ì, ÆÒµ¥¹Í ÀÌÈÄ Áö¿ª ½ÃÀå ¼ºÀå¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÇ·á±â±â »óȯ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ¸¹Àº ¹Î°£±â¾÷ÀÌ ÁøÀÔÇϸ鼭 2022³â ¸ÅÃâ Á¡À¯À²ÀÌ 65.0%¸¦ ³Ñ¾î ¹Î°£ °áÁ¦±â°üÀÌ ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
  • ÇコÄɾî ȯ°æº°·Î´Â º´¿ø ºÎ¹®ÀÌ ÃÖ±Ù ±â¼ú ¹ßÀü°ú ÇコÄÉ¾î ±â±â »ç¿ëÀ» ÇÊ¿ä·Î Çϴ ȯÀÚ ¼ö Áõ°¡·Î ÀÎÇØ 2022³â 51.8% ÀÌ»óÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº ³óÃÌ ¹× µµ½Ã Áö¿ª¿¡¼­ÀÇ º¸Çè ¼­ºñ½º º¸±Þ·ü Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀÇ·á±â±â »óȯ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ÀÇ·á±â±â »óȯ ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ÀÇ·á±â±â »óȯ : ÁöºÒÀÚº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ÀÇ·á±â±â »óȯ ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
  • ÀÇ·á±â±â »óȯ ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
  • °ø°ø
  • ¹Î°£

Á¦5Àå ÀÇ·á±â±â »óȯ : ÇコÄɾî ȯ°æº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ÀÇ·á±â±â »óȯ ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
  • ÀÇ·á±â±â »óȯ ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
  • º´¿ø
  • ¿Ü·¡ ½Ã¼³
  • ±âŸ

Á¦6Àå ÀÇ·á±â±â »óȯ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° Àü¸Á
  • Áö¿ªº° ÀÇ·á±â±â »óȯ ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
  • ºÏ¹Ì
    • ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦7Àå °æÀï »óȲ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
  • ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
    • UnitedHealth Group
    • Cigna
    • Humana Inc.
    • Allianz
    • Aviva
    • CVS Health
    • WellCare Health Plans
    • Nippon Life Insurance Company
    • BNP Paribas
    • Anthem Insurance Companies, Inc.
ksm 23.10.31

Medical Devices Reimbursement Market Growth & Trends:

The global medical devices reimbursement market size is expected to reach USD 1028.2 billion by 2030, expanding at a CAGR of 8.8% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Medical device reimbursement is defined as the payment a third-party private or public insurer pays a healthcare provider for the cost incurred while using medical equipment. The major factors fueling the industry growth are growing dependence on reimbursement, the increasing prevalence of chronic diseases, and growing preventive care. Focus on early diagnostics and preventive care may in turn lead to higher activity within the diagnostic device industry, thus promoting more reimbursement share from them.

For instance, a fundamental paradigm shift towards incentivizing early diagnosis through reimbursement has been noticed across developed economies, such as thorough screening for breast cancer. During the COVID-19 pandemic, surgeries such as robotic-assisted procedures were postponed. However, during the pandemic recovery period, these surgeries are expected to improve particularly in Asia pacific as the countries such as Japan and China are actively involved in providing reimbursement to robotic-assisted providers to improve the accuracy of surgeries. Such initiatives are likely to have a positive impact on market growth in the post-pandemic period. With an increasing demand for medical equipment, reimbursement services are expected to provide various opportunities for healthcare industries to poach upon. Additionally, the increasing number of people pursuing insurance and consolidation of the healthcare system are major factors fueling the industry growth.

North America dominated the market with a revenue share of over 50.2% in 2022 and is expected to maintain its dominance over the forecast period. The rising demand for healthcare equipment and the increasing number of healthcare centers are expected to drive the industry in this region. The growing prevalence of chronic diseases is driving the demand for various healthcare instruments. This is further expected to support the growth of the regional market. Over the years, the Centers for Medicare & Medicaid Services have reduced the reimbursement for diagnostic radiology in the U.S. For instance, in January 2022, a study published in Science Direct stated that, between 2011 - 2021, there was a steady decline in the reimbursement for diagnostic imaging studies. A continuation of this trend by the government agencies is expected to have a negative impact on the regional market growth in the post-pandemic period.

Medical Devices Reimbursement Market Report Highlights:

  • The private payer segment dominated the market with a revenue share of over 65.0% in 2022 due to the presence of a large number of private players
  • By healthcare setting, the hospitals segment held the largest revenue share of over 51.8% in 2022 due to recent technological developments and high patient footfall requiring the use of healthcare instruments
  • Asia Pacific is projected to witness rapid growth during the forecast period owing to the rising penetration of insurance services in rural and urban areas

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Payer
    • 1.1.2. Healthcare Setting
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Payer outlook
    • 2.2.2. Healthcare Setting outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Medical Device Reimbursement Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Medical Device Reimbursement Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Medical Device Reimbursement: Payer Estimates & Trend Analysis

  • 4.1. Medical Device Reimbursement Market: Key Takeaways
  • 4.2. Medical Device Reimbursement Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Public
    • 4.3.1. Public market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Private
    • 4.4.1. Private market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Medical Device Reimbursement: Healthcare Setting Estimates & Trend Analysis

  • 5.1. Medical Device Reimbursement Market: Key Takeaways
  • 5.2. Medical Device Reimbursement Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals
    • 5.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Outpatient facilities
    • 5.4.1. Outpatient facilities market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Medical Device Reimbursement Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Medical Device Reimbursement Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. UnitedHealth Group
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Cigna
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Humana Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Allianz
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Aviva
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. CVS Health
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. WellCare Health Plans
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Nippon Life Insurance Company
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. BNP Paribas
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Anthem Insurance Companies, Inc.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦